On 23 May 2011, the FDA held a telephone briefing to discuss two Direct Acting Antivirals (DAAs) with health care providers and patient advocates having an interest in treatment for hepatitis C. The call was intended to provide an overview of the safety and efficacy data and complexity of dosing regimens, and respond to questions about the use of these recently approved protease inhibitors, indicated as part of combination drug therapy, for the treatment of hepatitis C.
The call was initiated in response to comments at the FDA Antiviral Drugs Advisory Committee meeting in April, suggesting that additional information would be helpful in understanding the use of boceprevir and telaprevir drugs in clinical care.
A record of the teleconference (approximately 50 minutes) is available as a transcript and podcast.
Download Audio Recording Podcast (22 MB)
Labeling for these DAAs are available on the FDA web site:
Patient information for advocates
Links to external websites are current at time of posting but not maintained.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|